Page last updated: 2024-11-05

4-biphenylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-biphenylamine: used in detection of sulfates, & as a carcinogen in cancer research; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

biphenyl-4-amine : An aminobiphenyl that is biphenyl substituted by an amino group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7102
CHEMBL ID44201
CHEBI ID1784
SCHEMBL ID62469
MeSH IDM0049487

Synonyms (90)

Synonym
BB 0246764
p-aminodiphenyl
nsc7660
4-biphenylamine
p-aminobiphenyl
biphenylamine
4-aminodiphenyl
p-biphenylamine
p-phenylaniline
xenylamine
4-phenylaniline
p-xenylamine
nsc-7660
xenylamin
wln: zr dr
4-aminodifenil
[1,1'-biphenyl]-4-amine
4-biphenylylamine
aniline, p-phenyl-
AC-907/25014308
biphenyl-4-ylamine
4-amino-1,1'-biphenyl
paraaminodiphenyl
CHEBI:1784 ,
inchi=1/c12h11n/c13-12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9h,13h
biphenyl-4-amine
NCGC00091372-01
(1,1'-biphenyl)-4-amine
ai3-00124
nsc 7660
ccris 26
xenylamin [czech]
hsdb 1325
4-aminobifenyl [czech]
einecs 202-177-1
4-bifenylamin [czech]
brn 0386533
4-aminodifenil [spanish]
STK315364
4-aminobiphenyl
92-67-1
CHEMBL44201
AKOS000114495
MLS002303005
smr000062444
HMS1722B15
A844308
NCGC00091372-02
NCGC00091372-03
unii-16054949hj
4-12-00-03241 (beilstein handbook reference)
4-aminobifenyl
4-bifenylamin
16054949hj ,
HMS3091M12
cas-92-67-1
dtxsid5020071 ,
dtxcid9071
tox21_200376
NCGC00257930-01
(4-phenyl-phenyl)-amine
1,1'-biphenyl-4-amine; 4-biphenylylamine; 4-phenylaniline
BP-11958
(1,1'-biphenyl-4-yl)amine
4-aminobiphenyl [iarc]
1,1'-biphenyl-4-amine
4-biphenylamine [hsdb]
p-biphenylamine [mi]
CS-B0270
SCHEMBL62469
4-phenyl aniline
para-aminobiphenyl
4-amino-biphenyl
p-amino diphenyl
4-aminodiphenyl-d9
mfcd00007879
J-519854
F0096-0021
GS-3083
4-aminobiphenyl, analytical standard
4-aminobiphenyl 10 microg/ml in cyclohexane
[1,1'-biphenyl]-4-ylamine (acd/name 4.0)
[1,1'-biphenyl]-4-amine (acd/name 4.0)
xenylamin (czech)
{[1,1'-biphenyl]-4-amine}
4-aminodifenil (spanish)
BCP25781
Q229922
116267-93-7
EN300-17141

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Age-related changes in the expression of xenobiotic biotransformation enzymes can result in differences in the rates of chemical activation and detoxification, affecting responses to the therapeutic and/or toxic effects of chemicals."( Neonatal ontogeny of murine arylamine N-acetyltransferases: implications for arylamine genotoxicity.
Chau, B; McQueen, CA, 2003
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
" An analog/digital hybrid computer was then utilized to construct a multicompartmental pharmacokinetic model for ABP and its metabolites that separates: (a) absorption; (b) hepatic metabolism and distribution in blood and tissues; (c) ABP-hemoglobin adduct formation; (d) hydrolysis and reabsorption in the urinary bladder lumen; and (e) excretion."( Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl.
Bailey, JR; Benson, RW; Butler, MA; Dooley, KL; Kadlubar, FF; Roberts, DW; Skipper, PW; Tannenbaum, SR; Teitel, CH; Young, JF, 1991
)
0.28

Compound-Compound Interactions

ExcerptReferenceRelevance
" The proposed method was based on two-dimensional online solid phase extraction combined with liquid chromatography tandem mass spectrometry (SPE/LC-MS/MS)."( Rapid determination of six carcinogenic primary aromatic amines in mainstream cigarette smoke by two-dimensional online solid phase extraction combined with liquid chromatography tandem mass spectrometry.
Bie, Z; Chen, Y; Ji, L; Lu, W; Ren, H; Zhu, Y, 2017
)
0.46
"In this work, a rapid and sensitive thin-layer chromatography combined with surface-enhanced Raman spectroscopy method was established for rapid detection of benzidine and 4-aminobiphenyl in migration from food contact materials based on Au nanoparticle doped metal-organic framework."( Thin-layer chromatography combined with surface-enhanced Raman scattering for rapid detection of benzidine and 4-aminobiphenyl in migration from food contact materials based on gold nanoparticle doped metal-organic framework.
Cai, G; Ge, K; Hu, Y; Li, G; Ouyang, X, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" A mathematical estimation of the risk caused by a certain height of exposure is usually done under the assumption of a linear dose-response relationship by means of an arithmetical factor which gives the ratio of risk to dose in the low-response range and which has to be found on the basis of epidemiological or experimental data."( [Methods of risk assessment from data of experimental carcinogenesis studies].
Csicsaky, M; Pott, F; Roller, M, 1992
)
0.28
" The dose-response relationship between the amount of tobacco smoked and level of 4-aminobiphenyl-hemoglobin adducts in the slow acetylators (with an immediate steep increase of the adducts) was different from that in the fast acetylators (with a more regular increase)."( Interindividual variation in carcinogen metabolism and bladder cancer risk.
Ronco, G; Vineis, P, 1992
)
0.28
" The data indicate that at least in hepatocellular tumours of the C57Bl/10J strain and using chronic dosing regimes the ras genes do not represent markers for in vivo genotoxic activity."( Point mutation analysis of ras genes in spontaneous and chemically induced C57Bl/10J mouse liver tumours.
Hardaker, KJ; Lord, PG; Loughlin, JM; Marsden, AM; Orton, TC, 1992
)
0.28
" Preliminary experiments were performed to test the applicability of the preparative monoclonal antibody immunoaffinity column to isolate [3H]4-aminobiphenyl-derived metabolites in dosed rat and dog urine."( Monoclonal antibodies and rabbit antisera recognizing 4-aminobiphenyl--DNA adducts and application to immunoaffinity chromatography.
Donahue, PR; Groopman, JD; Kadlubar, FF; Skipper, PL; Tannenbaum, SR; Trudel, LJ; Wildschutte, M, 1992
)
0.28
" Rats dosed with nitrosobenzene (56 mumol/kg), 4-chloronitrosobenzene (53 mumol/kg), 3,4-dichloronitrosobenzene (53 mumol/kg), 4-ethoxynitrosobenzene (86 mumol/kg), 4-nitrosobiphenyl(nitroso-BP, 55 mumol/kg) or 2-nitrosofluorene (256 mumol/kg) had maximal ferrihaemoglobin (HbFe3+) concn of 69, 68, 69, 67, 55 and 42% after 15, 25, 48, 35, 80 and 115 min, respectively, indicating differences in solubility of the nitrosoarenes in body fluids."( The metabolism of 4-aminobiphenyl in rat. IV. Ferrihaemoglobin formation by 4-aminobiphenyl metabolites.
Karreth, S; Lenk, W, 1991
)
0.28
" dosing of ABP to dogs, the major portion of the total N-OH-ABP entering the bladder lumen was free N-OH-ABP (0."( Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl.
Bailey, JR; Benson, RW; Butler, MA; Dooley, KL; Kadlubar, FF; Roberts, DW; Skipper, PW; Tannenbaum, SR; Teitel, CH; Young, JF, 1991
)
0.28
" of the 24-48 h urine of rats dosed with 4-aminobiphenyl (ABP) showed that 4-acetylaminobiphenyl (AABP), 4'-hydroxy-4-aminobiphenyl(4'-hydroxy-ABP), 2'-hydroxy-4-acetylaminobiphenyl(2'-hydroxy-AABP), 4'-hydroxy-4-acetylaminobiphenyl(4'-hydroxy-AABP), 3'-hydroxy, 4'-methoxy-4-acetylaminobiphenyl (3'-hydroxy-4'methoxy-AABP), 4'-hydroxy, 3'-methoxy-4-acetylaminobiphenyl (4'-hydroxy-3'-methoxy-AABP), and 3',4'-dihydroxy-4-acetylaminobiphenyl(3',4'-dihydroxy-AABP) are urinary metabolites."( The metabolism of 4-aminobiphenyl in rat. III. Urinary metabolites of 4-aminobiphenyl.
Karreth, S; Lenk, W, 1991
)
0.28
" Convex dose-response relationships were found between the amount smoked and ABP hemoglobin adduct levels or urinary mutagenicity."( Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers.
Bartsch, H; Caporaso, N; Coda, M; Kadlubar, F; Malaveille, C; Skipper, P; Talaska, G; Tannenbaum, SR; Vineis, P, 1990
)
0.28
" A dose-response relationship between the number of cigarettes smoked per day and 4-ABP adduct level was observed, but did not account for the higher adduct levels observed in smokers of black tobacco."( Haemoglobin adducts of aromatic amines in people exposed to cigarette smoke.
Bryant, MS; Skipper, PL; Tannenbaum, SR; Vineis, P, 1988
)
0.27
" The purpose of this study was: (1) to determine whether or not changes that occurred in the plasma protein patterns were specific to 4-ABP and/or other related carcinogenic arylamines; (2) to measure the time course in the changes of the major polypeptides during dosing and their resynthesis during a recovery period; and (3) to determine, by microsequencing, the biochemical identity of the affected proteins."( Plasma proteins as early biomarkers of exposure to carcinogenic aromatic amines.
Benjamin, T; Dooley, KL; Kadlubar, FF; Miller, MJ; Parmelee, DC; Sechi, S, 1994
)
0.29
" Dose-response data are given also for mixtures including coal tar pitch condensate, centrifuged particles obtained from tap water, and water concentrates prepared with XAD-2 resin."( Rapid assay of cytotoxicity using Tetramitus flagellates.
Jaffe, RL,
)
0.13
" Chronic dosing experiments in animal models are of interest for human risk assessment because human exposure is typically intermittent, involving repeated exposures."( Aromatic amine DNA adduct formation in chronically-exposed mice: considerations for human comparison.
Beland, FA; Poirier, MC, 1997
)
0.3
" The repeat dosing protocol was therefore more sensitive than the single dose protocol."( Mutagenicity of the human bladder carcinogen 4-aminobiphenyl to the bladder of MutaMouse transgenic mice.
Ashby, J; Fletcher, K; Tinwell, H, 1998
)
0.3
" Correlation analysis of the principal components showed that lead could not significantly change the relation of hemoglobin adduct with time after dosing 4-aminobiphenyl."( Effects of lead on 4-aminobiphenyl pharmacokinetics in liver, kidney, spleen, testes, heart, lung and hemoglobin adduct for rat model.
Chen, HM; Qin, T; Xu, XB; Zhao, LX, 2002
)
0.31
" Two kinds of optimized linear models modified from the traditional dose-response model were screened out."( Synergic and competitive inhibition effect between two kinds of arylamines in the formation of hemoglobin adduct in vitro.
Chen, HM; Qin, T; Xu, XB, 2003
)
0.32
" We observed a dose-response relationship for 4-ABP dosage and DNA repair capacity (luc activity)."( A modified host cell reactivation assay to measure DNA repair capacity for removing 4-aminobiphenyl adducts: a pilot study of bladder cancer.
Kadlubar, FF; Lin, J; Spitz, MR; Wu, X; Zhao, H, 2005
)
0.33
" In this study, we compared in vivo ABP-induced DNA mutant frequencies and spectra between male and female wild-type and NAT-deficient Muta™Mouse using both the tumor-inducing neonatal exposure protocol and a 28-day repetitive dosing adult exposure protocol."( Influence of arylamine N-acetyltransferase, sex, and age on 4-aminobiphenyl-induced in vivo mutant frequencies and spectra in mouse liver.
Brenneman, D; Calce, A; Grant, DM; Hsu, I; Sugamori, KS; Wang, S, 2012
)
0.38
"CurveP is a heuristic, user-tunable, curve-cleaning algorithm that attempts to find a minimum set of corrections, which would give a monotonic dose-response curve."( CurveP Method for Rendering High-Throughput Screening Dose-Response Data into Digital Fingerprints.
Sedykh, A, 2016
)
0.43
" A gene dose-response relationship was exhibited as intermediate acetylators catalyzed 4-aminobiphenyl N-acetylation both in vitro and in situ at rates arithmetically between rapid and slow acetylators."( N-acetyltransferase 2 acetylator genotype-dependent N-acetylation of 4-aminobiphenyl in cryopreserved human hepatocytes.
Doll, MA; Habil, MR; Hein, DW, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
aminobiphenylAny member of the class of biphenyls in which the biphenyl skeleton is substituted by at least one amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Xenobiotics450
Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2110

Protein Targets (41)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency28.18380.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886; AID893
LuciferasePhotinus pyralis (common eastern firefly)Potency57.94870.007215.758889.3584AID1224835
BRCA1Homo sapiens (human)Potency17.78280.89137.722525.1189AID624202
ClpPBacillus subtilisPotency28.18381.995322.673039.8107AID651965
pregnane X receptorRattus norvegicus (Norway rat)Potency50.11870.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency11.14900.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency17.70310.000714.592883.7951AID1259368; AID1259369
AR proteinHomo sapiens (human)Potency13.65600.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743054
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency5.31700.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency1.98630.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency49.06760.003041.611522,387.1992AID1159552; AID1159553
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency18.07120.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency28.05750.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.95340.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743079; AID743080; AID743091
aryl hydrocarbon receptorHomo sapiens (human)Potency43.73150.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency1.57780.001723.839378.1014AID743083
histone deacetylase 9 isoform 3Homo sapiens (human)Potency37.97460.037617.082361.1927AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency45.26720.000627.21521,122.0200AID651741; AID720636
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.58930.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency70.47720.001557.789015,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency70.47720.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 1A4Homo sapiens (human)Km66.00007.00007.00007.0000AID214939
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
bilirubin conjugationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
heme catabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
retinoic acid bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID551126Inhibition of human recombinant MAOB expressed in insect cells at 100 uM by fluorescence assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID167927Carcinogenic activity on all sites after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1306173Cytotoxicity against human MCF7 cells assessed as reduction in cell growth after 3 days by MTT assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID167951Carcinogenic activity on ear duct after oral administration of the compound; - denotes non carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID214939Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1306172Cytotoxicity against human HT-29 cells assessed as reduction in cell growth after 3 days by MTT assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID168112Carcinogenic activity after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1306175Therapeutic index, ratio of IC50 for HEK293 cells to IC50 for human MCF7 cells2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1306174Therapeutic index, ratio of IC50 for HEK293 cells to IC50 for human HT-29 cells2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID551125Inhibition of human recombinant MAOA expressed in insect cells at 100 uM by fluorescence assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues.
AID168085Carcinogenic activity on liver after oral administration of the compound1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID167938Carcinogenic activity on breast after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID1306171Cytotoxicity against HEK293 cells assessed as reduction in cell growth after 3 days by MTT assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (308)

TimeframeStudies, This Drug (%)All Drugs %
pre-199074 (24.03)18.7374
1990's90 (29.22)18.2507
2000's77 (25.00)29.6817
2010's56 (18.18)24.3611
2020's11 (3.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.69 (24.57)
Research Supply Index5.79 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.31%)5.53%
Reviews23 (7.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other301 (92.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]